Relationship between blood clots and COVID-19 vaccines: A literature review
Seyed Mohammad Hassan Atyabi, Foad Rommasi, Hossein Ramezani, Mohammad Fazel Ghane Ezabadi, Mehdi AghaAmooi Arani, Mohammad Hossein Sadeghi, Mohammad Mehdi Ahmed, Amir Rajabi, Nima Dehghan, Ali Sohrabi, Mojtaba Seifi, Mohammad Javad Nasiri
Abstract
SARS-CoV-2 pandemic is one of the most critical pandemics during human civilization. Several therapeutic strategies for COVID-19 management have been offered; nonetheless, none of them seems to be sufficiently beneficial. In effect, vaccines have been proffered as a viable option. The critical issue now is to concentrate on protecting individuals against illness through immunization. One of the causes for concern among the researchers, physicians, and generally the whole community from the onset of vaccination has been the adverse effects (specifically blood clots) that may be observed after the injection of the COVID-19 vaccine. In some countries, such concerns have even resulted in the temporary or permanent discontinuation or abandonment of the application of some vaccines (especially AstraZeneca and Janssen). By evaluating rigorous studies published on this subject, the present article is aimed at identifying the association between blood clot incidence and COVID-19 vaccination. Various methods for producing the COVID-19 vaccines are analyzed, along with their possible pros and cons as well as common and rare side effects, especially VITT and blood clots. Finally, the differences of various vaccines on thrombotic events, WHO recommendations for VITT treatment, and blood clots statics are discussed.